Appel à projets : PHRCK (2015)
Titre : ISILI-01 (In Situ Immunotherapy in LIver metastases) An open-label, dose-finding, phase I study of intratumoral ipilimumab and TLR4 agonist in combination with systemic chemotherapy (FOLFOX regimen) in patients with colorectal liver metastases
Acronyme : ISILI-01
Discipline principale : Cancer
Porteur : David MALKA
Établissement : INSTITUT GUSTAVE ROUSSY (CLCC), Île-de-France
Financement total : 714728 €